Výsledky vyhledávání - "KARI T. RANTA"

718-P: Patients Achieving an HbA1c <5.7% with =5% Weight Loss and without Hypoglycemia: A Post Hoc Analysis of SURPASS 1 to 5

Autor: ALICE Y. CHENG, ILDIKO LINGVAY, PRATIK CHOUDHARY, ELISA GOMEZ-VALDERAS, SHERYL ALLEN, KARI T. RANTA, JOSHUA A. LEVINE, VIVIAN THIEU

Publikováno v: Diabetes. 71

In the phase 3 SURPASS studies of tirzepatide (TZP) , a novel dual GIP/GLP-1 receptor agonist developed for the treatment of type 2 diabetes, 23%-62% of TZP-treated participants achieved a HbA1c Disclosure A.Y. Cheng: Advisory Panel; Abbott, AstraZen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::269c45da8172246fc1ab46ec04031d6c
https://doi.org/10.2337/db22-718-p

Zobrazit plný text záznamu

673-P: Effect of Once-Weekly Dulaglutide 3.0 and 4.5 mg in Patients with Different Baseline Renal Function: Post-hoc Analysis from the Award-11 Trial

Autor: Kari T. Ranta, Juan M. Maldonado, Sohini Raha, Luis-Emilio Garcia-Perez

Publikováno v: Diabetes. 70

Background: AWARD-11 study in patients with type 2 diabetes on metformin demonstrated similar safety and superior efficacy of dulaglutide (DU) 3.0 and 4.5 mg vs. DU 1.5 mg. A post hoc analysis assessed consistency in safety and efficacy of the three

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::85dd05d3bcc62482fddc4d95390ae478
https://doi.org/10.2337/db21-673-p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání